Atossa Therapeutics Inc (NASDAQ:ATOS) Stock Under Pressure On FDA Setback
Atossa Therapeutics Inc (NASDAQ:ATOS) is down 20% in a month. The company announced its Q2 2021 financial results and offered corporate updates on recent development. In Q2, the company received final findings from the open-label Phase II clinical study of oral Endoxifen during the “window of opportunity” between breast cancer diagnosis and surgery. Endoxifen achieved the primary endpoint in the study with a 65.1% reduction of Ki-67, which is a…